CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating

Neutral
AI Analysis

Summary

RBC Capital Markets reduced its price target on CG Oncology from $81 to $79 while maintaining an Outperform rating with speculative risk designation.

Importance:2/10
Sentiment:
-0.10
price_target_adjustmentanalyst_rating
Related Companies

Read the original article

Published by yahoo_finance on August 7, 2026 11:15 AM

Read Original